Calgary, Alberta – May 15, 2025 - TheNewswire – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTCQB:NDATF)  has released Sigmund v.4, the Corporation’s advanced mental predisposition assessment. Sigmund includes a custom, purpose-built extensive life-variables database, a custom DNA panel with GWAS qualified depression-specific DNA markers, machine-learning/AI correlation algorithms, EEG-calibrated formulas and clinically-studied depression calibrations. Sigmund also incorporates a payment system to facilitate sales and an affiliate program to support visibility.

 

Today’s release targets the Concierge Health vertical that caters to affluent, health-conscious high-performance individuals across the fields of business, sports, arts and science. Other verticals are planned to be released this year. Sigmund and be seen at https://sigmundml.com.

 

NDAT’s President, James Durward, states: “Sigmund started out as “Shaman” approximately 4 years ago, then evolved to “YMI”, and then to CMCP-5”. While previous versions were already advanced applications, in my opinion, Sigmund today represents the most advanced emotional state assessment of its kind for those seeking a baseline from which to optimize their mental and physical performance. Sigmund can also function as an assessment support tool for the medical profession and a performance predictor for C-suite executive hires. The broadness of its application holds significant potential in multiple fields.”

 

For Further Information, please contact:

 

Jim Durward, President, CEO/CTO

Email: jimd@ndatalyze.com    

nDatalyze Website: https://www.ndatalyze.com      

 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.